Cargando…

Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma

BACKGROUND: In the phase III METEOR trial, tyrosine kinase inhibitor cabozantinib significantly improved progression-free survival (PFS), objective response rate (ORR), and overall survival compared to everolimus in patients with advanced renal cell carcinoma (RCC) who had received prior VEGFR inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lacy, Steven, Nielsen, Jace, Yang, Bei, Miles, Dale, Nguyen, Linh, Hutmacher, Matt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973957/ https://www.ncbi.nlm.nih.gov/pubmed/29667066 http://dx.doi.org/10.1007/s00280-018-3579-7

Ejemplares similares

A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types
por: Lacy, Steven, et al.
Publicado: (2018)

Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma
por: Nguyen, Linh, et al.
Publicado: (2019)

Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma
por: Nakagawa, Takashi, et al.
Publicado: (2022)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2022)

Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade
por: Kelley, Robin Kate, et al.
Publicado: (2021)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
por: Kelley, Robin K., et al.
Publicado: (2020)

Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
por: Krens, Stefanie D., et al.
Publicado: (2022)

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
por: Vecchio, Sharon J. Del, et al.
Publicado: (2018)

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017)

Cabozantinib‐induced renal thrombotic microangiopathy
por: La Manna, Gaetano, et al.
Publicado: (2017)

Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection
por: Yu, Steven S, et al.
Publicado: (2016)

Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma
por: Nakaigawa, Noboru, et al.
Publicado: (2023)

Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
por: Tran, Benjamin Duy, et al.
Publicado: (2023)

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
por: Rathi, Nityam, et al.
Publicado: (2020)

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
por: Bersanelli, Melissa, et al.
Publicado: (2017)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
por: Iuliani, Michele, et al.
Publicado: (2021)

Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma
por: Park, Keon Young, et al.
Publicado: (2021)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
por: Colomba, Emeline, et al.
Publicado: (2022)

Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study
por: Sazuka, Tomokazu, et al.
Publicado: (2023)

Safety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients
por: Bank, J. R., et al.
Publicado: (2015)

Exposure‐toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer
por: Krens, Stefanie D., et al.
Publicado: (2021)

Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
por: Kapur, Sakshi, et al.
Publicado: (2014)

Impact of Cabozantinib Exposure on Proteinuria and Muscle Toxicity in Patients with Unresectable Hepatocellular Carcinoma
por: Okubo, Hironao, et al.
Publicado: (2022)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice
por: Grassi, Paolo, et al.
Publicado: (2016)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
por: Bersanelli, Melissa, et al.
Publicado: (2018)

An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives
por: Iaxx, Romain, et al.
Publicado: (2022)

Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis
por: Bang, Yeong Hak, et al.
Publicado: (2022)

Modulation of cabozantinib efficacy by the prostate tumor microenvironment
por: Tripathi, Manisha, et al.
Publicado: (2017)

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
por: Storandt, Michael H., et al.
Publicado: (2022)

A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma
por: Kessler, Elizabeth R., et al.
Publicado: (2023)

Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma
por: Gerendash, Benjamin S, et al.
Publicado: (2017)

Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma
por: Uche, An, et al.
Publicado: (2019)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
por: Grassi, Paolo, et al.
Publicado: (2016)

Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib
por: Boustany, Johnny, et al.
Publicado: (2020)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma
por: Emberley, Ethan, et al.
Publicado: (2021)

Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
por: Zhang, Qing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fre9ff1tuf1jdt3h491ifirnk0